AZD 5213

Drug Profile

AZD 5213

Alternative Names: AZD5213

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Analgesics; Nootropics; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Diabetic neuropathies; Gilles de la Tourette's syndrome; Mild cognitive impairment

Most Recent Events

  • 01 May 2015 AstraZeneca completes a phase II trial for painful Diabetic neuropathies in USA (NCT01928381)
  • 01 Feb 2015 AstraZeneca completes a phase II trial in Tourette's syndrome (in adolescents) in USA (NCT01904773)
  • 01 Nov 2013 Phase-II clinical trials in Diabetic neuropathies in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top